Kinase inhibitor drugs [electronic resource] / Rongshi Li, Jeffrey A. Stafford.
A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the...
Saved in:
| Online Access: |
Full Text (via Wiley) |
|---|---|
| Main Author: | |
| Other Authors: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hoboken, N.J. :
J. Wiley,
©2009.
|
| Series: | Wiley series in drug discovery and development.
|
| Subjects: |
Table of Contents:
- The discovery and development of sunitinib (SU11248)
- Tykerb discovery : a dual EGFR and erbB2 tyrosine kinase inhibitor
- Discovery of pazopanib, a potent pan vascular endothelial growth factor inhibitor in clinical development
- The road to ABT-869, a multi-targeted receptor tyrosine kinase inhibitor
- Discovery of motesanib
- The discovery of brivanib alaninate, a dual vascular endothelial growth factor and fibroblast growth factor receptor inhibitor
- Structure-based design and characterization of axitinib
- The road to PD0325901 and beyond : the MEK inhibitors quest
- The discovery of allosteric MEK inhibitors
- The discovery of MK-0457 (VX-680)
- Discovery of PHA-739358
- The discovery of AZD1152 : a selective inhibitor of aurora B kinase with potent anti-tumor activity
- Case study of aurora A inhibitor MLN8054
- The discovery of GSK461364a
- Pharmacogenomics of dasatinib
- Practical use of computational chemistry in kinase drug discovery
- Approaches to kinase homology modeling : successes and consideration for the structural kinome
- Fragment-based drug discovery of kinase inhibitors
- Protein kinase structural biology : methods and strategies for targeted drug discovery.